Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial

Inclusion criteria

Participants are eligible only if all of the following criteria apply:

Age

• Participant must be more than 18 years old inclusive, at the time of signing the informed consent.

Type of Participant and Disease Characteristics

• Individuals with a clinical diagnosis of actinic keratosis (AK).
• Individuals harboring 5 or more clinically recognizable (palpable and/or visible to unaided eye) AK lesions of the face, and/or ears and/or scalp. The AK lesions must be clinically typical non hypertrophic and/or nonhyperkeratotic.
• Subject in good general condition and free of any disease state or condition which, in the investigator's opinion, could impair evaluation of actinic keratosis or could expose the subject to an unacceptable risk by study participation.

Sex

• Male or female. A Female participant is eligible to participate if she is not a woman of childbearing potential (WOCBP), defined as postmenopausal (cessation of menses >12 months) or surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, total hysterectomy).

Informed Consent

• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Ethical/Legal considerations

• Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation).

Exclusion criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions

• With AK lesions within treatment areas which are hyperkeratotic or which are clinically suspected to be squamous cell carcinoma (SCC).
• With pre-existing local skin reactions with a total score ≥ 3.
• History of hypersensitivity to the ingredients of Tolak® or Dexeryl®.
• With a known allergy to peanut or soya.
• Non postmenopausal or non surgically sterile woman considered as WOCBP, pregnant or breastfeeding women.

Prior/Concomitant Therapy

• Under systemic 5-fluorouracil or any systemic cancer treatment within eight weeks prior to the study.
• Under any other topical AK treatments or therapies (e.g., Cryotherapy or Photodynamic therapy) in the treatment area(s) within eight weeks prior to starting the study.
• Treated with systemic steroids, immunosuppressants or immunomodulators within four weeks prior to the study.
• Under prescription retinoids or topical steroids in the treatment area(s) within four weeks prior to the study.
• With known dihydropyrimidinedehydrogénase (DPD) deficiency or under treatment with brivudine, sorivudine or analogues within 4 weeks prior to starting the study.
• Treated with glycolic acid products and alpha-hydroxy products in the treatment area(s) within four weeks prior to starting the study.
• Treated with chemical peeling products in the treatment area(s) within eight weeks prior to starting the study.

Prior/Concurrent Clinical Study Experience

• Is participating in another clinical trial
• Has participated in another clinical trial within the last 30 days, has received treatment with known remnant effects or undergone investigation liable to interfere with the present clinical trial Other Exclusions
• Is a family member of the Investigator or any associate, colleague, and employee assisting in the conduct of the study (secretary, nurse, technician,…)
• Is in a position likely to represent a conflict of interest
• Has forfeited his / her freedom by administrative or legal award or is under guardianship